Biobetters market seen topping $121.61 billion by 2030

10 hours ago
Biobetters market seen topping $121.61 billion by 2030
By AI, Created 17:15 UTC, Nov 20, 2026, AGP -

The global biobetters market is projected to grow from $75.29 billion in 2025 to $121.61 billion by 2030, according to The Business Research Company. Demand is rising on chronic disease growth, autoimmune conditions and broader adoption of improved biologic therapies.

Why it matters: - The biobetters market is moving from niche biologics into a larger treatment category as health systems look for therapies with better dosing, safety and patient convenience. - The projected jump to $121.61 billion by 2030 signals sustained demand across chronic and autoimmune disease care. - The growth outlook matters for drug developers, investors and providers focused on biologic innovation.

What happened: - The Business Research Company released its Biobetters Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 20, 2026. - The report pegs the market at $75.29 billion in 2025 and $83.84 billion in 2026. - The market is forecast to grow at a 11.4% CAGR in 2026 and 9.7% CAGR through 2030, reaching $121.61 billion by 2030. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Biobetters are biologic drugs based on existing biologics but improved for clinical performance. - The category can offer better dosing regimens, fewer side effects, improved stability and more convenient administration. - The report cites chronic kidney disease as a major demand driver. - CKD prevalence in the UK is expected to rise 4%, from 0.00827 billion in 2022 to 0.00861 billion by 2032, according to research published by Oxford Academic in June 2023. - The report also points to autoimmune diseases as another growth engine. - The September 2023 Impact of IBD Report from the IBD Clinical and Research Centre in Canada said inflammatory bowel disease affected 825 per 100,000 people, or more than 0.00032 billion individuals. - That IBD figure is projected to reach 0.00047 billion by 2035. - The report says broader market growth is supported by rising chronic disease rates, greater acceptance of biosimilars, biotechnology advances, supportive government policies and an aging population. - It also cites wider adoption of biobetters over original biologics, drug delivery innovation, expanding healthcare infrastructure in emerging markets, biopharma collaborations and demand for personalized treatments. - The report says market trends include improved effectiveness and safety, optimized dosing schedules, better drug stability and shelf life, easier administration and broader chronic disease use. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company said its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables. - More information is available in the full biobetters market report. - A free sample of the report is also available.

Between the lines: - The forecast suggests biobetters are gaining traction as a higher-value alternative to older biologics rather than just a minor formulation tweak. - Chronic kidney disease and autoimmune disease are doing the heavy lifting in the demand story because both are long-term conditions that reward better adherence and dosing convenience. - The regional split points to a mature North American market and faster room for expansion in Asia-Pacific.

What's next: - Market growth is likely to track progress in drug delivery, biologic engineering and personalized medicine. - Expansion in emerging-market healthcare systems could widen access and accelerate adoption. - The next market inflection will likely come from whether more biobetters can show clear clinical or operational advantages over original biologics.

The bottom line: - Biobetters are forecast to become a much larger part of the biologics market by 2030, powered by chronic disease demand and a push for better-performing therapies.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Middle East Political Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Middle East Political Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.